HeartBeam Inc. (NASDAQ: BEAT) has been awarded two new U.S. patents, strengthening its position in remote cardiac diagnostics. These patents protect the company's compact, cable-free 3D ECG device and a rhythm analysis algorithm designed to detect arrhythmias through continuous signal input. This advancement marks a crucial step toward making advanced cardiac care available beyond conventional medical settings.
The 3D ECG device uses chest and finger electrodes to capture high-fidelity cardiac signals from three non-coplanar directions. This technology enables on-demand symptom recording and the synthesis of 12-lead ECGs, providing a comprehensive view of heart electrical activity. Currently under FDA review, the device's software has been validated by data from the VALID-ECG pivotal study, highlighting its potential to transform cardiac monitoring. More information about the company's technology can be found at https://www.heartbeam.com/technology.
HeartBeam's rhythm analysis algorithm improves diagnostic precision by identifying abnormal heart rhythms and triggering targeted data collection. This feature is adaptable across various cardiac monitoring systems, promising enhanced accuracy in arrhythmia detection and management. Together, these technologies address the critical need for portable, reliable cardiac diagnostics that can be deployed anywhere. The company's patent portfolio now includes 20 issued patents and 34 pending filings, positioning it at the forefront of digital cardiac care innovation.
Future plans involve integrating artificial intelligence capabilities to further boost diagnostic accuracy, enabling smarter cardiac health management solutions. These developments aim to transform cardiac care by facilitating early detection and intervention, potentially improving patient outcomes and reducing healthcare system burdens. HeartBeam's platform represents the first cable-free 12-lead ECG device capable of capturing three-dimensional heart electrical signals, empowering physicians with actionable intelligence to identify cardiac trends and acute conditions outside traditional settings. By redefining cardiac health management, the company is establishing new standards for patient care and diagnostic precision. Additional details about HeartBeam's innovations are available at https://www.heartbeam.com.
